Kristin Comella is a world renowned expert on regenerative medicine, with an expertise in stem cells. She was listen in Terrapin’s list of the Top 50 Global Stem Cell Influencers and was number 1 on the Academy of Regenerative Practices list of Top 10 Stem Cell Innovators. Kristin has led the way in stem cell therapies from a variety of sources, including cord blood, bone marrow, muscle, and adipose.
Kristin led the team that gained the first ever FDA approval for a clinical trial using a combined cell and gene therapy product in the heart. In addition, she also handles managing the development, manufacturing, and quality systems of cellular products.
Kristin has held positions in several companies including US Stem Cell, Stemlogix, Tulane University and Osiris Therapeutics. She was co-founder and CEO of Stemlogix, and is currently serving as the Chief Scientific Officer, and board member, of US Stem Cell, focusing on the discovery, development, and commercialization of autologous cell therapies for the treatment of degenerative diseases.
Key Takeaways:
[4:15] How the body uses stem cells inserted into the body
[7:25] A surprising place a mass of stem cells can be found
[12:20] Why stem cell therapies have been gaining traction in the past few years
[15:40] The typical price range of stem cell therapy
[18:20] Whether Fernando's decision not to bank his child's cord blood was a mistake
[23:30] Using stem cell therapy for aesthetic purposes
[26:40] How US Stem Cells can verify the results of therapy
Websites:
